Compare CBC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | SRRK |
|---|---|---|
| Founded | 1902 | 2012 |
| Country | United States | United States |
| Employees | 3036 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.5B |
| IPO Year | N/A | 2018 |
| Metric | CBC | SRRK |
|---|---|---|
| Price | $29.48 | $53.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $28.67 | ★ $56.17 |
| AVG Volume (30 Days) | 792.5K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $6.34 | $534.24 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $27.07 |
| 52 Week High | $29.92 | $53.86 |
| Indicator | CBC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 69.08 |
| Support Level | $26.86 | $45.46 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.85 | 2.24 |
| MACD | 0.06 | 1.02 |
| Stochastic Oscillator | 85.11 | 86.85 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.